<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220077</url>
  </required_header>
  <id_info>
    <org_study_id>2110</org_study_id>
    <nct_id>NCT00220077</nct_id>
  </id_info>
  <brief_title>Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer</brief_title>
  <official_title>Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <brief_summary>
    <textblock>
      Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy
      regimens for individual patients. It could ensure that patients do not receive a particular
      form of chemotherapy if it is unlikely to benefit them, and in these circumstances an
      alternative form of chemotherapy that may prove beneficial could be selected. This
      information will therefore allow chemotherapy to be tailored to the individual tumour. It may
      help identify those patients with a poorer prognosis who could be selected for further
      therapy post surgery or a different treatment strategy at the outset.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Oesophageal Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with histologically proven operable ,locally advanced and metastatic
             oesophageal or gastric carcinoma.

        Exclusion Criteria:

          -  Second malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheela Rao</last_name>
    <phone>0208 642 6011</phone>
    <email>sheela.rao@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naureen Starling</last_name>
    <phone>0208 642 6011</phone>
    <email>naureen.starling@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Rao</last_name>
      <phone>0208 642 6011</phone>
      <email>sheela.rao@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Starling</last_name>
      <phone>0208 642 6011</phone>
      <email>naureen.starling@rmh.nhs</email>
    </contact_backup>
    <investigator>
      <last_name>David Cunningham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

